DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INLYTA

Clinical Trials for Inlyta

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00700258	Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]	Recruiting	Pfizer	N/A	The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use
NCT01321437	Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma	Active, not recruiting	Pfizer	Phase 2	The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
NCT01321437	Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma	Active, not recruiting	University of California, Irvine	Phase 2	The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
NCT01529138	Study of Axitinib and Temsirolimus in Solid Tumors	Completed	Pfizer	Phase 1	This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial.
NCT01529138	Study of Axitinib and Temsirolimus in Solid Tumors	Completed	Emory University	Phase 1	This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial.
NCT01533948	Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery	Terminated	National Cancer Institute (NCI)	Phase 2	This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01533948	Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery	Terminated	National Comprehensive Cancer Network	Phase 2	This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Trial ID	Title	Status	Sponsor	Phase	Summary